KDR and gastric cancer: Ramucirumab, a fully humanized IgG1 monoclonal anti-vascular endothelial growth factor receptor 2 antibody, and checkpoint inhibitors in EBV and microsatellite-unstable (MSI) subtypes have proven beneficial in advanced GC (34).